Association of Survival With Adjuvant Chemotherapy Among Patients With Early-Stage Non–Small Cell Lung Cancer With vs Without High-Risk Clinicopathologic Features | Zendy

Ranjan Pathak | Zendy; Sarah B. Goldberg | Zendy; Maureen Canavan | Zendy; Jeph Herrin | Zendy; Jessica R. Hoag | Zendy; Michelle C. Salazar | Zendy; Marianna V. Papageorge | Zendy; Theresa Ermer | Zendy; Daniel J. Boffa | Zendy

Open Access

Association of Survival With Adjuvant Chemotherapy Among Patients With Early-Stage Non–Small Cell Lung Cancer With vs Without High-Risk Clinicopathologic Features

Author(s) -

Ranjan Pathak,

Sarah B. Goldberg,

Maureen Canavan,

Jeph Herrin,

Jessica R. Hoag,

Michelle C. Salazar,

Marianna V. Papageorge,

Theresa Ermer,

Daniel J. Boffa

Publication year - 2020

Publication title -

jama oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 8.846

H-Index - 99

eISSN - 2374-2445

pISSN - 2374-2437

DOI - 10.1001/jamaoncol.2020.4232

Subject(s) - medicine , lung cancer , oncology , chemotherapy , stage (stratigraphy) , adjuvant chemotherapy , adjuvant , cancer , breast cancer , paleontology , biology

Tumor size larger than 4 cm is accepted as an indication for adjuvant chemotherapy in patients with node-negative non-small cell lung cancer (NSCLC). Treatment guidelines suggest that high-risk features are also associated with the efficacy of adjuvant chemotherapy among patients with early-stage NSCLC, yet this association is understudied.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research